Skip to main content
HCPCS J1301 · Level II · Part B drug

HCPCS J1301: Injection, edaravone, 1 mg

Reviewed by QuickIntell RCM Editorial Team · Last reviewed

Data effective
Data currency: ASP payment limits October 2026 (effective October 1, 2026); MUE and NCCI edits 2026 Q4 (effective October 1, 2026); OPPS Addendum B July 2026 (effective July 1, 2026). Next CMS release: January 1, 2027 (ASP, MUE, NCCI and OPPS quarterly updates).

Key facts for J1301

Billing unit
1 MG
Injection, edaravone, 1 mg
ASP payment limit
$6.375
October 2026; -1.4% vs July 2026
Practitioner MUE
60
MAI 3
OPPS status
SI K
APC 9493
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J1301 is the Level II code for Injection, edaravone, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $6.375 per billing unit, down 1.4% from July 2026. The practitioner MUE allows up to 60 units per date of service (MAI 3). Under OPPS it carries status indicator K in APC 9493. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. The ASP crosswalk maps 4 NDCs to it, sold as Edaravone, Radicava by Sandoz Inc., XGen Pharmaceuticals DJB, Inc., Piramal Critical Care Inc. No current Billing and Coding Article lists J1301, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J1301 at $6.375 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $6.463 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J1301
QuarterPayment limitPerCoinsurance
October 2026$6.3751 MG20%
July 2026$6.4631 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 4 NDCs from 4 labelers to J1301. Report the NDC in the claim's drug segment and bill the number of J1301 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to J1301
NDCDrug nameLabelerPackage sizeBilling units / package
00781-3527-20EdaravoneSandoz Inc.100 × 260
39822-4500-02EdaravoneXGen Pharmaceuticals DJB, Inc.100 × 230
66794-0259-64EdaravonePiramal Critical Care Inc100 × 260
70510-2171-02RadicavaMitsubishi Tanabe Pharma America, Inc.100 × 260

Medically Unlikely Edits (MUE)

CMS publishes 2 MUE values for J1301. For practitioners the limit is 60 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J1301 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services603 Date of Service Edit: ClinicalPrescribing Information
Facility outpatient hospital603 Date of Service Edit: ClinicalPrescribing Information

NCCI edits and add-on relationships

No active practitioner PTP pair lists J1301 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

J1301 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J1301 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the July 2026 OPPS Addendum B, J1301 carries status indicator K and is assigned to APC 9493, with a published national unadjusted payment of $6.46. Status K means the drug is paid separately under OPPS at the ASP-based rate rather than packaged into the procedure.

Common denials for J1301 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

How QuickIntell checks J1301 before the claim leaves

QuickCode validates the NDC-to-unit conversion against the current ASP crosswalk, checks units against every published MUE setting and flags PTP and add-on conflicts on the same claim. QuickRCM routes CARC 16, 151 and 50 denials on drug lines with the matching coverage article attached so the appeal starts with evidence.

Frequently asked questions — HCPCS J1301

What does HCPCS code J1301 describe?

J1301 is defined by CMS as "Injection, edaravone, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

What is the Medicare reimbursement for J1301 in October 2026?

The ASP-based payment limit is $6.375 per 1 MG, with 20% beneficiary coinsurance. Medicare Administrative Contractors apply this limit; commercial payers use their own fee schedules. The July 2026 limit was $6.463.

How many units of J1301 can be billed per day?

The practitioner Medically Unlikely Edit is 60 units per date of service with adjudication indicator 3 (3 Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Prescribing Information" as the rationale.

Which NDCs map to J1301?

The October 2026 ASP crosswalk lists 4 NDCs from 4 labelers: Edaravone (Sandoz Inc.); Edaravone (XGen Pharmaceuticals DJB, Inc.); Edaravone (Piramal Critical Care Inc); Radicava (Mitsubishi Tanabe Pharma America, Inc.). For example NDC 00781-3527-20 is a 100 package equal to 60 billing units. The crosswalk's billing-units-per-package figure converts each package into J1301 units.

Does J1301 have NCCI bundling edits?

No active practitioner PTP pairs list J1301 as a column-1 or column-2 code in the v323r0 release. Unit limits (MUE) and medical-necessity coverage rules still apply.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-01. Verify against the primary file before billing or contracting decisions.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B and the Medicare Coverage Database. Payment limits are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.